

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 053466/0274		SERIAL NO. 09 509,098	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT Masayuki TSUCHIYA		RECEIVED OCT 19 2000 1648 OCT 23 2000 ATTACH TO #4	
				FILING DATE 3/22/2000			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	TECH CENTER IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
LAP	A1	Tetsuya Goto et al., "A Novel Membrane Antigen Selectively Expressed on Terminally Differentiated Human B Cells.", Blood, vol. 84, No. 6, pp. 1922-1930, September 15, 1994					
LJ	A2	Peter T. Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse.", Nature, vol. 321, pp. 522-525, May 29, 1986					
LJP	A3	Catherine A. Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation.", Protein Engineering, vol. 4, No. 7, pp. 773-783, 1991					
LQD	A4	Cary Queen et al., "A humanized antibody that binds to the interleukin 2 receptor.", Proceedings of the National Academy of Science, vol. 86, pp. 10029-10033, December 1989					
LJM	A5	Lutz Riechmann et al., "Reshaping human antibodies for therapy.", Nature, vol. 332, pp. 323-327, March 24, 1988					
LJN	A6	Koh Sato et al., "Humanization of a Mouse Anti-Human Interleukin-6 Receptor Antibody Comparing Two Methods for Selecting Human Framework Regions.", Molecular Immunology, vol. 31, No. 5, pp. 371-381, 1994					
Lmb	A7	Man Sung Co et al., "Humanized antibodies for antiviral therapy.", Proceedings of the National Academy of Science, vol. 88, pp. 2869-2873, April 1991					
LH	A8	Martine Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity.", Science, vol. 239, pp. 1534-1536, March 25, 1988					
EXAMINER				DATE CONSIDERED			
				7/30/01			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 053466/0274		SERIAL NO. 09/509098 UNASSIGNED	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				APPLICANT <div style="text-align: right;">Masayuki TSUCHIYA</div>		09/509098	
				FILING DATE <div style="text-align: center;">March 22, 2000</div>			
				GROUP ART UNIT <div style="text-align: center;">Unassigned</div>			
U.S. PATENT DOCUMENTS ATTACH TO #3							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
L10	A1	M.A. ROGUSKA et al., "A comparison of two murine monoclonal antibodies humanized by CDR-grafting and Variable domain resurfacing", <u>Protein Engineering, Vol. 9, No. 10</u> , pp. 895-904, (1996)					
L2	A2	J.T. PEDERSEN et al., "Comparison of surface accessible residues in human and murine immunoglobulin Fv domains", <u>J. Mol. Biol., Vol. 235</u> , pp. 959-973, (1994)					
L3	A3	M.A. ROGUSKA et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing", <u>Proc. Natl. Acad. Sci. USA, Vol. 91</u> , pp. 969-973, (1994)					
EXAMINER [Signature]				DATE CONSIDERED 7/20/01			
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.							